Study Shows Low Infection Rates for Aroa Biosurgery's Soft Tissue Scaffold
A 411-patient study on Aroa Biosurgery's Myriad scaffold in complex soft tissue reconstruction has reported low infection rates. The interim analysis of the MASTRR Registry is among the largest prospective bioscaffold studies published.
Aroa Biosurgery Limited, a company focused on soft tissue regeneration, has released findings from a study indicating low infection rates associated with its Myriad scaffold. The research, involving 411 patients undergoing complex soft tissue reconstruction, was published in a peer-reviewed journal.
The interim analysis of the MASTRR Registry, a prospective study, focused on the use of bioscaffolds in inpatient soft tissue reconstruction. This represents a significant dataset within the field, according to Aroa Biosurgery.
The company did not provide specific infection rate figures in its announcement, but highlighted the positive outcome of low rates. Further details are expected to emerge as the registry analysis continues.
Soft tissue reconstruction is a critical surgical procedure for patients with trauma, defects, or after cancer surgery. The development of effective biomaterials like scaffolds aims to improve healing and reduce complications such as infection.